Safety and Tolerability Evaluation of MaaT033
NCT04150393
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
Hematologic Diseases
Chemotherapy Effect
Interventions
DRUG:
MaaT033 capsule
Sponsor
MaaT Pharma